Alok A. Khorana, MD, FACP, FASCO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Scott T. Tagawa, MD
Associate Professor of Clinical Medicine
Associate Professor of Clinical Urology
Medical Director, Genitourinary Oncology Research Program
Assistant Attending Physician, New York-Presbyterian Hospital (Cornell campus)
New York, NY
This enduring activity will cover the treatment and management of VTE in patients with cancer.
This activity is intended for US-based community oncologists and oncology nurses involved in the management of VTE in patients with cancer.
After completing the CME activity, learners should be better able to:
- Summarize current guideline recommendations for the treatment of VTE in patients with cancer
- Describe completed and ongoing trials comparing the efficacy and safety of DOACs and low molecular weight heparins (LMWHs) for the treatment of VTE in patients with cancer
- Discuss completed and ongoing clinical trials assessing the efficacy and safety of DOACs for thromboprophylaxis in patients with cancer
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the treatment and management of patients with VTE.
CNE Credits: 1.0 ANCC Contact Hour.
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Alok Khorana reports that he has served as a consultant for Janssen, Bayer, Pfizer, and Sanofi.
Dr. Scott Tagawa reports that he has served as a consultant for Medivation, Astellas, Dendreon, Janssen, Bayer, Genentech, Endocyte, Immunomedics, Karyopharm, Abbvie, Tolmar, QED, Amgen, Sanofi, and Pfizer. In addition, he has received grant funding from Lilly, Sanofi, Janssen, Astellas, Progenics, Millennium, Amgen, BMS, Dendreon, Rexahn, Bayer, Genentech, Newlink, Inovio, AstraZeneca, Immunomedics, Novartis, AVEO, Boehringer Ingelheim, Merck, Karyopharm, Abbvie, Medivation, Endocyte, Exelexis, and Clovis.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Program Manager for Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this web-based enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Complete the pre/post-test.
4. Complete online evaluation form.
You will receive your certificate after completion of the evaluation.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: March 11, 2020
EXPIRATION DATE: March 11, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.